Empagliflozin and major renal outcomes in heart failure
Open accessAbstract
Empagliflozin and Renal Outcomes in Heart Failure In a planned pooled analysis of two trials that evaluated empagliflozin in patients with heart failure, major adverse renal outcomes occurred in 2....
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
A previous meta-analysis had limited power as only 98 kidney disease progression outcomes were reported in participants without diabetes in heart failure trials.
“a previous meta-analysis had limited power as only 98 kidney disease progression outcomes were reported in participants without diabetes in such trials.1, 11”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 6 · Cited by 112
- Authors
- Packer, M., Butler, J., Zannad, F., Pocock, S. J., Filippatos, G., Ferreira, J. P., Brueckmann, M., Jamal, W., Zeller, C., Wanner, C., & Anker, S. D.
- Affiliations
- Baylor College of Medicine (US)
- University of Mississippi Medical Center (US)
- Centre d'Investigation Clinique Pierre Drouin (FR)
- London School of Hygiene & Tropical Medicine (GB)
- National and Kapodistrian University of Athens (GR)
- Boehringer Ingelheim (Germany) (DE)
- University of Würzburg (DE)
- Charité – Universitätsmedizin Berlin (DE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-10-14
- Volume
- 385
- Issue
- 16
- Pages
- 1531-1533
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3193316662
- Cited by
- 112
- References
- 6
- Citations by year
- 2026: 9 · 2025: 8 · 2024: 17 · 2023: 27 · 2022: 39 · 2021: 11 · 2020: 1
- FWCI
- 15.92
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
- HAL (submittedVersion)
- Funders
- Boehringer Ingelheim
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Keywords
- empagliflozin, heart failure, renal outcomes, SGLT2 inhibitors
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Benzhydryl Compounds, Diabetes Mellitus, Type 2, Glomerular Filtration Rate, Glucosides, Heart Failure, Hospitalization, Humans, Kidney Diseases, Stroke Volume, Renal Replacement Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
